19 results about "Dosing Frequency" patented technology

The invention discloses an application and a preparation of a miR-125b-5p inhibitor or antagonist for treating and / or preventing myopia. According to the application, a miR-125b-5p inhibitor or antagonist, particularly miR-125b-5p antiagomir with a nucleotide sequence as shown in SEQ ID NO: 8, is used for inhibiting the expression of miR-125b-5p in sclera and increasing the expression of a target gene tp53, so that the transdifferentiation of sclera fibroblasts can be remarkably reduced, sclera remodeling can be reduced, and the diopter reduction and ocular axis extension of guinea pig deprivation myopia can be retarded; the composition can be used for preventing myopia and controlling myopia progress, has the advantages of low administration frequency and high safety, and provides a safer, more effective and more convenient prevention and control means for myopia patients, especially teenagers.

The present invention relates to therapeutic compositions and methods for the treatment of attention deficit disorder (ADD), or attention deficit hyperactivity disorder (ADHD). The present invention more particularly relates to a modified-release pharmaceutical formulation designed to improve the delivery and efficacy of central nervous system (CNS) stimulants. The composition consists of a drug-containing core with a CNS stimulant and pharmaceutically acceptable excipients. This core is coated with a sustained-release (SR) layer comprising one or more polymers selected from water-insoluble and water-insoluble pH-dependent polymers, and one or more pharmaceutically acceptable excipients which regulates the gradual release of the drug. Surrounding the SR layer is a delayed-release (DR) outer layer that controls the onset of drug release. This approach aims to enhance symptom control, reduce dosing frequency, and improve patient compliance in the treatment of ADD and ADHD.

The present invention provides an antibody or antigen-binding portion thereof that can bind to properdin (factor P). The antibody of the current invention leads to selective inhibition of alternative complement pathway while allowing the classical and lectin pathways to continue. Further, the antibody of the present invention may have modified or reduced binding to FcγRs to minimize its ADCC activity. The present invention provide an antibody that comprises an amino acid sequence to minimise its CDC activity. The antibody according to the present invention has higher FcRn binding affinity and therefore the antibody according to the present invention may have long circulating half-life in the body of the patient and it can be given at a reduced dosing frequency. The antibody according to the present invention can further be used in the preparation of a drug for treating diseases through inhibition of alternative complement pathway.

The disclosure provides improved human FGF23-binding antibodies with increased affinity for human FGF23 as compared to burosumab, enabling reduced dosing frequency, improving convenience of therapy, and achieving higher efficacy compared to burosumab, without compromising safety.

The present invention relates to therapeutic compositions and methods for the treatment of attention deficit disorder (ADD), or attention deficit hyperactivity disorder (ADHD). The present invention more particularly relates to a modified-release pharmaceutical formulation designed to improve the delivery and efficacy of central nervous system (CNS) stimulants. The composition consists of a drug-containing core with a CNS stimulant and pharmaceutically acceptable excipients. This core is coated with a sustained-release (SR) layer comprising one or more polymers selected from water-insoluble and water-insoluble pH-dependent polymers, and one or more pharmaceutically acceptable excipients which regulates the gradual release of the drug. Surrounding the SR layer is a delayed-release (DR) outer layer that controls the onset of drug release. This approach aims to enhance symptom control, reduce dosing frequency, and improve patient compliance in the treatment of ADD and ADHD.

This invention relates to wastewater treatment control technology, and discloses an intelligent carbon source dosing system and method for wastewater treatment with load sensing and allocation functions. The method includes: carbon source dosing, which involves adding carbon source to the anoxic tank and denitrification tank via a carbon source dosing pump unit; controlling the carbon source dosing frequency, which involves controlling the carbon source dosing frequency of the carbon source dosing pump unit via a carbon source dosing pump control cabinet; and feeding back the carbon source dosing amount to the carbon source dosing pump control cabinet; and determining the carbon source dosing amount, which is controlled by the intelligent carbon source dosing system through controlling the frequency of the carbon source dosing pump unit. The control of the carbon source dosing amount is achieved by controlling the carbon source dosing pump unit through the intelligent carbon source dosing system. This invention can detect the carbon source dosing amount in real time, and it offers good safety, low cost, and simple operation.

An autoserum eye drop administration device comprises a bottle body, a bottom cover and a bottle mouth, an arc-shaped tunnel is arranged in the bottle body, the upper end of the arc-shaped tunnel extends to the bottle mouth, the lower end of the arc-shaped tunnel extends to the bottom cover, a liquid medicine capsule is contained in the arc-shaped tunnel, a separation opening is formed in the side wall of the arc-shaped tunnel, one end of an elastic button is exposed out of the bottle body, and the other end of the elastic button extends to the separation opening. Extruding the liquid medicine capsule; the bottle neck is in threaded connection with the bottle body, a fine needle is arranged in the bottle neck, a fine needle reserved opening is formed in the upper portion of the arc-shaped tunnel, and the bottle neck is rotated to enable the fine needle to enter the arc-shaped tunnel from the fine needle reserved opening and pierce the liquid medicine capsule. By means of the structure, the autoserum eye drop dosing device can be matched with a liquid medicine capsule to conduct autoserum eye drop dosing, pollution is not prone to occurring, the dosing frequency can be increased, and waste is not prone to being caused.

The present invention relates to an injectable formulation, a method for treating a metabolic disease and an administration device. The injectable formulation comprises a lipid matrix composition, a specific amount of a GLP-1 receptor agonist and at least one pharmaceutically acceptable ion. Accordingly, upon contacting an aqueous fluid, the injectable formulation forms a depot exhibiting an extended release of the GLP-1 receptor agonist in vivo or in vitro. In the method for treating the metabolic disease, the injectable formulation can be administered to a subject with a reduced dosing frequency, and it is not necessary to store the injectable formulation for the next administration. For the administration device, the injectable formulation is filled in a vial, a pre-filled syringe or a pre-filled cartridge. Therefore, the injectable formulation can be designed for a single use, thereby enhancing convenience, compliance and adherence of a subject.

The application discloses a kind of cannabidiol heat-sensitive nano hydrogel preparation and its injection and its preparation method, the injection includes cannabidiol 5-15mg / mL, Poly (I:C) 0.5-1.5mg / mL and Pluronic F127 concentration is 20-30wt%.The injection can slow-release cannabidiol and Poly (I:C) and prolong its residence time at tumor site, reduce dosing frequency, effectively and continuously synergistic inhibition tumor, reduce side effects.

The present invention relates to the field of peptide drugs, and particularly to a triple-target peptide and a derivative thereof. The triple-target peptide provided by the present invention exerts effects of lowering blood glucose, reducing blood lipids, and weight loss. Based on the above studies, the triple-target peptide provided by the present invention is further long-acting modified, and while retaining excellent effects for the specific indications described above, also has long-acting advantages, which can reduce dosing frequency, improve medication convenience, and enhance patient compliance. Experimental results show that the peptide and the long-acting derivative thereof provided by the present invention can significantly lower blood glucose, reduce blood lipids and / or induce weight loss, and can effectively prevent, treat, or ameliorate diabetes, obesity, obesity-related diseases, or metabolic disorders.

Provided is a transdermal drug delivery system comprising tetrahydrocannabinol (THC). Transdermal delivery can provide a drug plasma concentration at predetermined rate for a predetermined period of time with a simplified therapeutic regimen by decreasing dosing frequency for the treatment and / or prevention of pain and / or inflammation.

To provide a treatment option that provides an extended duration of therapeutic action while reducing dosing frequency in the treatment of diabetes.SOLUTION: Provided are compounds comprising a therapeutic polypeptide Fc conjugate having activity at one or more of the GIP, GLP-1, and glucagon receptors. These compounds provide activity at one or more of these receptors and have structural features that extend the duration of action. Also provided are methods for treating diseases and / or conditions such as obesity, chronic weight management, and type 2 diabetes.SELECTED DRAWING: None

The present invention relates to the field of therapy. More particularly, the present invention relates to therapeutic methods in which effector components are administered that require cellular uptake to become effective and / or exert their effect via intracellular (molecular) targets, such as but not limited to nucleic acid or oligonucleotide therapeutic agents. The present invention provides modes that extend the duration of the effect of the effector component and / or extend the interval of administration of the effector component and / or reduce the frequency of administration of the effector component and / or cause a (delayed) enhancement of the effect of the effector component.

The present application relates to tap water data processing technical field, disclose two stage gradual tap water dosing quantity optimization method based on deep learning, including steps: input sequence data of current time into model M1, output predicted dosing frequency of distribution pool of current time, and turbidity at the end of filter pool of next time; adjust the predicted dosing frequency of distribution pool of current time, obtain the actual dosing frequency of distribution pool of current time;Optimization model M2 is trained using database;After training, input sequence data of current time, artificially set distribution pool dosing frequency selection sequence into optimization model M2, output predicted turbidity at the end of filter pool of next time;With optimal turbidity at the end of filter pool as target, adjust the actual dosing frequency of distribution pool of current time.The present application solves the data set and hysteresis problem existing when implementing intelligent control, and can realize the optimization control of flocculation reagent dosing through successive adjustment on the basis of risk control.

The invention relates to the technical field of water treatment, and discloses a leachate Fenton treatment process based on a water pollution control agent, which comprises the following steps: adding a composite catalytic agent composed of an iron-based component and a copper graphite component into leachate, adding an oxidizing agent in a pulse mode, and monitoring an oxidation-reduction potential response curve, an instantaneous reaction factor is calculated according to the curve integral area, the dosing delay interval and the pump output frequency are adjusted according to the comparison result of the instantaneous reaction factor and a preset limit value, and the reaction circulating pump is controlled to generate fluid shear force within the delay interval to scour and strip a passivation layer on the surface of the agent. Physical synchronization of medicament injection and organic load degradation is realized, self-quenching of free radicals is inhibited, generation of chemical sludge is reduced, meanwhile, the alkalinity of the leachate is identified and compensated by utilizing potential signal characteristics, the stability of a catalytic environment is maintained, and the leachate treatment energy efficiency is improved.

The invention discloses a corrosion and scale inhibition and sterilization intelligent control system for a chemical circulating water system, and belongs to the technical field of chemical circulating water treatment. The system comprises an online water quality monitoring sensor, a circulating water flow sensor, a control unit, a variable-frequency dosing pump and a medicament storage unit which are arranged on a circulating water main pipeline, the online water quality monitoring sensor detects the pH value, hardness, conductivity and residual chlorine parameters of circulating water in real time, the control unit receives data of the sensor and analyzes the water quality trend through a built-in algorithm, the variable-frequency dosing pump is controlled to accurately add chemicals from the dosing tank, and meanwhile the dosing frequency is automatically adjusted according to the flow of the circulating water. And the dosing tank is provided with a liquid level sensor to monitor the residual amount of the medicament. The system realizes automatic monitoring of circulating water quality and accurate dosing, effectively maintains water quality stability, reduces medicament consumption, and guarantees safe and stable operation of the system.

Pharmaceutical compositions and medicaments comprising O-GlcNAcase inhibitors are provided, as well as respective dosing regimens for administration to human patients for the treatment of various disorders, such as proteopathies, including tauopathies, synucleinopathies, and neurological disorders such as Alzheimer's disease.SOLUTION: A pharmaceutical composition comprising a compound of formula (I) and / or tautomers thereof for use in a method of treatment of a human subject, the method comprising repeatedly administering one or more unit dosage forms comprising the compound of formula (I) and / or tautomers thereof at a dose and a daily dosing frequency sufficient to maintain plasma concentrations of the compound of formula (I) and / or tautomers thereof in the range of about 45 to about 2000ng / mL at trough, wherein a dose of the compound of formula (I) and / or tautomers thereof administered at the daily dosing frequency is administered orally and ranges from about 150 to about 500mg.SELECTED DRAWING: None

The present application relates to the field of water treatment, and specifically discloses a sewage circulating treatment equipment, which comprises a water treatment cylinder, a plurality of blades located in the water treatment cylinder, a rotating shaft fixedly connected with the plurality of blades, and a sealing structure for coaxial rotation of the rotating shaft on the water treatment cylinder, wherein the side walls of the blades away from the rotating shaft are attached to the inner wall of the water treatment cylinder, and the surfaces of adjacent two blades and the inner wall of the water treatment cylinder form a separation treatment cavity; a dosing control unit opposite to a single separation treatment cavity, wherein the dosing control unit comprises a dosing device, a PLC controller, a rotating speed sensor for detecting the rotating speed of the rotating shaft, and a dosing controller for controlling the dosing frequency of the dosing device; the dosing device is electrically connected with the dosing controller; the dosing controller and the rotating speed sensor are electrically connected with the PLC controller; and when the rotating speed of the rotating shaft detected by the rotating speed sensor changes, the dosing controller controls the dosing frequency of the dosing device to change proportionally.

The utility model relates to a dosing device and integrated sewage treatment equipment. The dosing device comprises a dosing shell and a dosing aeration pipe, and the dosing shell and the treatment tank in the integrated sewage treatment equipment form a buried structure, so that cooling and heat preservation effects on the dephosphorization liquid medicine in the dosing shell are achieved, the stability of the dephosphorization liquid medicine can be prolonged, the shelf life of the dephosphorization liquid medicine is prolonged, and the dephosphorization efficiency is improved. The manual dosing frequency is reduced, and the maintenance and operation cost is reduced. The chemical outlet of the chemical adding shell and the communicating port between the aerobic chamber and the settling chamber are arranged up and down, and the action of adding chemical into the settling chamber can be realized by utilizing the gravity of the dephosphorization chemical liquid, so that the energy consumption and the equipment cost are saved, and the maintenance and operation cost is further reduced. The aeration device aerates the dosing shell through the dosing aeration pipe and stirs the dephosphorization liquid medicine in the dosing shell, and compared with a conventional paddle type stirring device, the same stirring effect is achieved, meanwhile, stirring energy consumption can be reduced, and the maintenance and operation cost is further reduced.